Press Releases
Search
-
25 Sep 2018
bioMérieux commitments in the CDC’s “AMR Challenge”, a joint public-private sector initiative to accelerate the fight against antimicrobial resistance
Marcy l’Étoile (France) – Sept. 25, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, is participating in the AMR Challenge, a new Centers for Disease Control and Prevention (CDC...
-
05 Sep 2018
First-Half 2018 Results
Strong sales dynamic, with sales up 10.4% over the first half at constant exchange rates and scope of consolidation: €1,169 million in sales Up 3.1% as reported Contributive operating income before no...
-
18 Jul 2018
Second-Quarter 2018 Business Review
Strong sales dynamic confirmed in second quarter, leading to sales up 10.4% over the first half at constant exchange rates and scope of consolidation: €1,169 million in sales Up 3.1% as reported Growt...
-
12 Jun 2018
NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in Acute Dialysis Quality Initiative Recommendations
The biomarkers in the NEPHROCHECK® test, an FDA-cleared and CE-marked urine test that indicates kidney stress in advance of acute kidney injury (AKI), have been included in a second set of consensus r...
-
31 May 2018
bioMérieux launches ENDOZYME® II GO, an innovative test for the detection of endotoxins in pharmaceutical microbiology control
bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of ENDOZYME® II GO, a new endotoxin test in the bioMérieux ENDONEXTTM range of recombinant horseshoe...
-
02 May 2018
NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in Groundbreaking Consensus Statement of Best Practices to Enhance Recovery after Heart Surgery
Marcy l’Étoile (France) and San Diego (California) - May 2nd, 2018 – The biomarkers in the NEPHROCHECK test, an FDA-cleared and CE-marked urine test that indicates kidney stress in advance of acute ki...